Karin HoogendoornHead Drug Product Development (CART, Oncology) at Galapagos BVSpeaker
Profile
With over 25 years of experience spanning the pharmaceutical industry from SME to big pharma and academia, Karin has played key roles in CMC-development and CMC- regulatory affairs across the full lifecycle of ATMP development, both in the Netherlands and abroad (Sweden, Switzerland, and Japan). Currently serving as head Drug Product Development CART at Galapagos BV (Leiden, the Netherlands), she brings a wealth of knowledge on CMC, including manufacturing, testing, and comparability strategies for cell and gene therapy products.
Agenda Sessions
Panel Discussion: Bringing Cell Therapy to the Patient—Implementing Decentralised Manufacturing
, 09:40View SessionHow to Show Comparability for Fresh (Non-Cryopreserved) Autologous Ex-Vivo Gene Therapy Products, Manufactured across a Network of Decentralised Manufacturing Sites
, 11:20View Session